Additional glycosylationwithin a specific hypervariable region of subtype 3a of hepatitis C virus protects against virus neutralization

Journal of Infectious Diseases

Volumn 208, Issue 11, 2013, Pages 1888-1897

  Anjum, Sadia ^a,b,c,d,e   Wahid, Ahmed ^a,b,c,d,g   Afzal, Muhammad Sohail ^a,b,c,d,e,f   Albecka, Anna ^j   Alsaleh, Khaled ^k   Ahmad, Tahir ^e   Baumert, Thomas F ^h   Wychowski, Czeslaw ^a,b,c,d   Qadri, Ishtiaq ^l   Penin, François ⁱ   Dubuisson, Jean ^a,b,c,d  

^a INSTITUT PASTEUR DE LILLE   (France)

^b Institut National de la Santé et de la Recherche Medicale U1019   (France)

^c INSERM U1019   (France)

^d UNIV LILLE   (France)

^e NATIONAL UNIVERSITY OF SCIENCES AND TECHNOLOGY   (Pakistan)

^f National Center of Virology and Immunology   (Pakistan)

^g Minia University   (Egypt)

^h UNIVERSITÉ DE STRASBOURG   (France)

ⁱ UNIVERSITÉ DE LYON   (France)

^j UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^k INSTITUT PASTEUR   (France)

^l KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

more..

Author keywords

Hepacivirus; Hepatitis C virus; Neutralizing antibodies; Sequence variability; Viral glycoproteins

Indexed keywords

GLYCOPROTEIN E2; NEUTRALIZING ANTIBODY; CD81 ANTIGEN; CD81 PROTEIN, HUMAN; EPITOPE; GLYCOPROTEIN E2, HEPATITIS C VIRUS; HEPATITIS C ANTIBODY; MONOCLONAL ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; EMBRYO; GENETIC VARIABILITY; GLYCOSYLATION; HEPATITIS C VIRUS; HEPATITIS C VIRUS SUBTYPE 3A; HUMAN; HUMAN CELL; NONHUMAN; PAKISTAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SENSITIVITY ANALYSIS; VIRUS ENTRY; VIRUS ISOLATION; VIRUS NEUTRALIZATION; AMINO ACID SEQUENCE; CELL LINE; CHEMISTRY; DNA SEQUENCE; GENETICS; HEPACIVIRUS; HEPATITIS C; IMMUNOLOGY; METABOLISM; MUTATION; SEQUENCE ALIGNMENT; VIROLOGY; SEQUENCE VARIABILITY; VIRAL GLYCOPROTEINS;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD81; CELL LINE; EPITOPES; GLYCOSYLATION; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; MUTATION; PAKISTAN; RNA, VIRAL; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA; VIRAL ENVELOPE PROTEINS;

HEPACIVIRUS; HEPATITIS C VIRUS; NEUTRALIZING ANTIBODIES; SEQUENCE VARIABILITY; VIRAL GLYCOPROTEINS;

EID: 84888588967     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit376     Document Type: Article

References (34)

1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17:107-15.
2. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436:967-72.
3. Dore GJ, Matthews GV, Rockstroh J. Future of hepatitis C therapy: development of direct-acting antivirals. Curr Opin HIV AIDS 2011; 6:508-13.
4. Vieyres G, Thomas X, Descamps V, Duverlie G, Patel AH, Dubuisson J. Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol 2010; 84:10159-68.
5. Edwards VC, Tarr AW, Urbanowicz R, Ball J. The role of neutralising antibodies in hepatitis C virus infection. J Gen Virol 2012; 93:1-19.
6. Helle F, Goffard A, Morel V, et al. The neutralizing activity of antihepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol 2007; 81:8101-11.
7. Helle F, Vieyres G, Elkrief L, et al. Role of N-linked glycans in the functions of HCV envelope proteins incorporated into infectious virions. J Virol 2010; 84:11905-15.
8. Krey T, d'Alayer J, Kikuti CM, et al. The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog 2010; 6:e1000762.
9. McCaffrey K, Boo I, Poumbourios P, Drummer HE. Expression and characterization of a minimal hepatitis C virus glycoprotein E2 core domain that retains CD81 binding. J Virol 2007; 81:9584-90.
10. Brown RJ, Tarr AW, McClure CP, et al. Cross-genotype characterization of genetic diversity and molecular adaptation in hepatitis C virus envelope glycoprotein genes. J Gen Virol 2007; 88:458-69.
11. Humphreys I, Fleming V, Fabris P, et al. Full-length characterization of hepatitis C virus subtype 3a reveals novel hypervariable regions under positive selection during acute infection. J Virol 2009; 83:11456-66.
12. Ausubel FM, Brent R, Kingston RE, et al. Current Protocols in Molecular Biology, Vol. 1. JohnWiley and Sons, Inc., New York 2000.
13. Combet C, Garnier N, Charavay C, et al. euHCVdb: The European hepatitis C virus database. Nucleic Acids Res 2007; 35:D363-6.
14. Combet C, Blanchet C, Geourjon C, Deleage G. NPS: network protein sequence analysis. Trends Biochem Sci 2000; 25:147-50.
15. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, positions-specific gap penalties and weight matrix choice. Nucleic Acids Research 1994; 22:4673-80.
16. Kuiken C, Mizokami M, Deleage G, et al. Hepatitis C databases, principles and utility to researchers. Hepatology 2006; 43:1157-65.
17. Flint M, Maidens C, Loomis-Price LD, et al. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol 1999; 73:6235-44.
18. Catanese MT, Ansuini H, Graziani R, et al. Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol 2010; 84:34-43.
19. Fofana I, Krieger SE, Grunert F, et al. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 2010; 139:953-64.
20. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 1982; 42:3858-63.
21. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C pseudoparticles containing functional E1E2 envelope protein complexes. J Exp Med 2003; 197:633-42.
22. Op De Beeck A, Voisset C, Bartosch B, et al. Characterization of functional hepatitis C virus envelope glycoproteins. J Virol 2004; 78:2994-3002.
23. Lavillette D, Tarr AW, Voisset C, et al. Characterization of host-range and cell entry properties of hepatitis C virus of major genotypes and subtypes. Hepatology 2005; 41:265-74.
24. Goueslain L, Alsaleh K, Horellou P, et al. Identification of GBF1 as a cellular factor required for hepatitis C virus RNA replication. J Virol 2010; 84:773-87.
25. Maurin G, Fresquet J, Granio O, Wychowski C, Cosset FL, Lavillette D. Identification of interactions in the E1E2 heterodimer of hepatitis C virus important for cell entry. J Biol Chem 2011; 286:23865-76.
26. Pietschmann T, Kaul A, Koutsoudakis G, et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A 2006; 103:7408-13.
27. Goffard A, Callens N, Bartosch B, et al. Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J Virol 2005; 79:8400-9.
28. Falkowska E, Kajumo F, Garcia E, Reinus J, Dragic T. Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. J Virol 2007; 81:8072-9.
29. Chaudhuri S, Das S, Chowdhury A, Santra A, Bhattacharya SK, Naik TN. Molecular epidemiology of HCV infection among acute and chronic liver disease patients in Kolkata, India. J Clin Virol 2005; 32:38-46.
30. Albecka A, Monserret R, Krey T, et al. Identification of new functional regions in hepatitis C virus envelope glycoproteins E2. J Virol 2011; 85:1777-92.
31. Bungyoku Y, Shoji I, Makine T, et al. Efficient production of infectious hepatitis C virus with adaptive mutations in cultured hepatoma cells. J Gen Virol 2009; 90:1681-91.
32. Delgrange D, Pillez A, Castelain S, et al. Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins. J Gen Virol 2007; 88:2495-503.
33. Helle F, Duverlie G, Dubuisson J. The hepatitis C virus glycan shield and evasion of the humoral immune response. Viruses 2011; 3:1909-32.
34. Belouzard S, Cocquerel L, Dubuisson J. Hepatitis C virus entry into the hepatocyte. Cent Eur J Biol 2011; 6:933-45.